These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9258810)

  • 21. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
    Brue T; Pellegrini I; Gunz G; Morange I; Dewailly D; Brownell J; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioactivity and glycosylation of circulating prolactin in various physiological and pathological conditions.
    Gambino GM; Beck-Peccoz P; Borgato S; Faglia G; Spada A; Persani L
    Pituitary; 1999 Nov; 2(3):225-31. PubMed ID: 11081158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.
    Duranteau L; Chanson P; Lavoinne A; Horlait S; Lubetzki J; Kuhn JM
    Clin Endocrinol (Oxf); 1991 Jan; 34(1):25-9. PubMed ID: 1672268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. Results of a clinical long-term study.
    Nickelsen T; Jungmann E; Althoff P; Schumm-Draeger PM; Usadel KH
    Arzneimittelforschung; 1993 Apr; 43(4):421-5. PubMed ID: 8098604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis.
    Broekhof R; Gosselink MJ; Pijl H; Giltay EJ
    Gen Hosp Psychiatry; 2012; 34(2):209.e1-3. PubMed ID: 21872335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
    Colao A; Loche S; Cappa M; Di Sarno A; Landi ML; Sarnacchiaro F; Facciolli G; Lombardi G
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2777-80. PubMed ID: 9709946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of macroprolactinomas with quinagolide (Norprolac)].
    Tabarin A; Catargi B
    Ann Endocrinol (Paris); 1997; 58(2):87-94. PubMed ID: 9239226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D; Lastoria S; Colao A; Varrella P; Cerbone G; Acampa W; Merola B; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of prolactinoma with a new dopamine agonist].
    Svoboda T; Luger A; Knosp E; Geyer G
    Dtsch Med Wochenschr; 1991 Aug; 116(33):1224-7. PubMed ID: 1678695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aldosterone response to metoclopramide in patients with prolactinoma: effect of short-term bromocriptine treatment.
    Zacharieva S; Stoeva I; Andreeva M; Kalinov K; Matrozov P; Andonova K
    Methods Find Exp Clin Pharmacol; 1996 Nov; 18(9):593-7. PubMed ID: 9010834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
    Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of radiotherapy and bromocriptine treatment in patients with previous surgery for macroprolactinomas.
    Moberg E; af Trampe E; Wersäll J; Werner S
    Neurosurgery; 1991 Aug; 29(2):200-4; discussion 204-5. PubMed ID: 1886657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma.
    Karavitaki N; Thanabalasingham G; Shore HC; Trifanescu R; Ansorge O; Meston N; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):524-9. PubMed ID: 16984247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
    Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
    Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance to bromocriptine in prolactinomas.
    Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
    J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolactinomas and resistance to dopamine agonists.
    Brue T; Pellegrini I; Priou A; Morange I; Jaquet P
    Horm Res; 1992; 38(1-2):84-9. PubMed ID: 1306523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Establishment of reference values for endocrine tests. II: Hyperprolactinemia.
    Le Moli R; Endert E; Fliers E; Mulder T; Prummel MF; Romijn JA; Wiersinga WM
    Neth J Med; 1999 Aug; 55(2):71-5. PubMed ID: 10474275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
    Primeau V; Raftopoulos C; Maiter D
    Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Some issues in the diagnosis and treatment of hyperprolactinemia].
    Jin ZM
    Zhonghua Fu Chan Ke Za Zhi; 2008 Apr; 43(4):241-3. PubMed ID: 18843959
    [No Abstract]   [Full Text] [Related]  

  • 40. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502.
    Barnett PS; Palazidou E; Miell JP; Coskeran PB; Butler J; Dawson JM; Maccabe J; McGregor AM
    Q J Med; 1991 Nov; 81(295):891-906. PubMed ID: 1687293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.